Larimar Therapeutics, Inc. (LRMR)

Larimar Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-80.6	-36.95	-35.36	-50.64	-42.48
Depreciation & Amortization	0.32	0.31	0.32	0.33	0.16
Loss (Gain) From Sale of Assets	-	-	-	-0	-
Loss (Gain) From Sale of Investments	-5.26	-1.84	-0.77	-0.01	0.01
Stock-Based Compensation	8.8	7.62	6.62	5.47	2.16
Other Operating Activities	-0.19	-0.08	-0.05	0.02	-
Change in Accounts Payable	1.14	-0.4	0.03	-0.97	-3.29
Change in Other Net Operating Assets	5.03	-2.11	1.64	3.71	1.25
Operating Cash Flow	-70.76	-33.46	-27.57	-42.11	-42.2
Capital Expenditures	-0.52	-0.16	-0.1	-0.33	-0.06
Cash Acquisitions	-	-	-	-	40.64
Investment in Securities	-84.87	33.52	-90.86	24.5	-23.49
Investing Cash Flow	-85.39	33.35	-90.96	24.17	17.09
Issuance of Common Stock	161.88	0.03	75.26	19.89	93.59
Financing Cash Flow	161.88	0.03	75.26	19.89	93.59
Net Cash Flow	5.74	-0.08	-43.27	1.95	68.48
Free Cash Flow	-71.28	-33.62	-27.67	-42.44	-42.26
Free Cash Flow Per Share	-1.16	-0.77	-1.07	-2.47	-3.56
Levered Free Cash Flow	-42.05	-20.84	-14.35	-23.09	-23.39
Unlevered Free Cash Flow	-42.05	-20.84	-14.35	-23.09	-23.39
Change in Net Working Capital	-6.16	2.5	-1.64	-2.98	-1.11

Updated Mar 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q